Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

Area of Science:

• Nephrology
• Endocrinology
• Clinical Risk Prediction

Background:

• Diabetic nephropathy is a leading cause of end-stage renal disease (ESRD).
• Accurate prediction of ESRD is crucial for patient management in type 2 diabetes.
• The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study provided a valuable dataset for risk factor analysis.

Purpose of the Study:

• To develop and validate a risk score for predicting ESRD in patients with type 2 diabetes and nephropathy.
• To compare the predictive ability of the developed risk score against its individual components.
• To assess the risk score's performance with and without considering death as an endpoint.

Main Methods:

• Multivariate analysis of baseline variables from the RENAAL study.
• Development of a risk score equation incorporating urinary albumin:creatinine ratio, serum albumin, serum creatinine, and hemoglobin.
• Comparison of hazard ratios for the risk score and its components across quartiles.

Main Results:

• A robust risk score was developed, independent of nephropathy severity, gender, race, and treatment.
• The risk score demonstrated a significantly higher hazard ratio (49.0) for ESRD between the highest and lowest quartiles compared to individual components.
• The risk score for ESRD with or without death showed comparable predictive ability.

Conclusions:

• The RENAAL risk score effectively predicts ESRD in type 2 diabetes patients with nephropathy.
• Albuminuria, serum albumin, serum creatinine, and hemoglobin are key predictors of ESRD.
• Combining these factors into a risk score enhances prediction accuracy beyond albuminuria alone.